Highly potent 5-aminotetrahydropyrazolopyridines: Enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions

Journal of Medicinal Chemistry

Volumn 54, Issue 7, 2011, Pages 2477-2491

  Tschammer, Nuska ^a   Elsner, Jan ^a   Goetz, Angela ^a   Ehrlich, Katharina ^a   Schuster, Stefan ^a   Ruberg, Miriam ^a   Kühhorn, Julia ^a   Thompson, Dawn ^b   Whistler, Jennifer ^b   Hübner, Harald ^a   Gmeiner, Peter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ASPARTIC ACID; CYCLIC AMP; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LIGAND; N [4 (4 PHENYLBENZOYLAMINO)BUTYL] N PROPYL 5 AMINO 4,5,6,7 TETRAHYDROPYRAZOLO[1,5 A]PYRIDINE; PERTUSSIS TOXIN; PRAZOSIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; QUINPIROLE; SPIPERONE; THYMIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENANTIOSELECTIVITY; HUMAN; HUMAN CELL; NONHUMAN; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

HEK293 CELLS; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; PROTEIN CONFORMATION; PYRAZOLES; PYRIDINES; RECEPTORS, DOPAMINE D3; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 79953775165     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101639t     Document Type: Article

References (78)

1. Neve, K. A.; Seamans, J. K.; Trantham-Davidson, H. Dopamine Receptor Signaling J. Recept. Signal Transduction Res. 2004, 24, 165-205 (Pubitemid 39332216)
2. Hindle, J. V. Ageing, Neurodegeneration and Parkinson's Disease Age Ageing 2010, 39, 156-161
3. Schetz, J. A. Pharmacotherapies for the Management of Parkinson's Disease Drug Topics 2001, 19, 52-61
4. Mayeux, R.; Denaro, J.; Hemenegildo, N.; Marder, K.; Tang, M.-X.; Cote, L. J.; Stern, Y. A Population-Based Investigation of Parkinson's Disease with and without Dementia: Relationship to Age and Gender Arch. Neurol. 1992, 49, 492-497
5. Lieberman, A.; Ranhosky, A.; Korts, D. Clinical Evaluation of Pramipexole in Advanced Parkinson's Disease: Results of a Double-Blind, Placebo-Controlled, Parallel-Group Study Neurology 1997, 49, 162-168 (Pubitemid 27328697)
6. Boeckler, F.; Leng, A.; Mura, A.; Bettinetti, L.; Feldon, J.; Gmeiner, P.; Ferger, B. Attenuation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Neurotoxicity by the Novel Selective Dopamine D3-Receptor Partial Agonist FAUC 329 Predominantly in the Nucleus Accumbens of Mice Biochem. Pharmacol. 2003, 66, 1025-1032 (Pubitemid 37083598)
7. Le, W. D.; Jankovic, J. Are Dopamine Receptor Agonists Neuroprotective in Parkinson's Disease Drugs Aging 2001, 18, 389-396 (Pubitemid 32531825)
8. van Vliet, L. A.; Rodenhuis, N.; Dijkstra, D.; Wikstrom, H.; Pugsley, T. A.; Serpa, K. A.; Meltzer, L. T.; Heffner, T. G.; Wise, L. D.; Lajiness, M. E.; Huff, R. M.; Svensson, K.; Sundell, S.; Lundmark, M. Synthesis and Pharmacological Evaluation of Thiopyran Analogues of the Dopamine D3 Receptor-Selective Agonist (4a R,10b R)-(+)- trans -3,4,4a,10b-Tetrahydro-4- n -propyl-2 H,5 H -[1]benzopyrano[4,3- b ]-1,4-oxazin-9-ol (PD 128907) J. Med. Chem. 2000, 43, 2871-2882 (Pubitemid 30599645)
9. Wikstroem, H.; Andersson, B.; Sanchez, D.; Lindberg, P.; Arvidsson, L. E.; Johansson, A. M.; Nilsson, J. L. G.; Svensson, K.; Hjorth, S.; Carlsson, A. Resolved Monophenolic 2-Aminotetralins and 1,2,3,4,4a,5,6,10b-Octahydrobenzo[ f ]quinolines: Structural and Stereochemical Considerations for Centrally Acting Pre- and Postsynaptic Dopamine-Receptor Agonists J. Med. Chem. 1985, 28, 215-225 (Pubitemid 15170887)
10. Titus, R. D.; Kornfeld, E. C.; Jones, N. D.; Clemens, J. A.; Smalstig, E. B.; Fuller, R. W.; Hahn, R. A.; Hynes, M. D.; Mason, N. R. Resolution and Absolute Configuration of an Ergoline-Related Dopamine Agonist, trans -4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1 H (or 2 H)-pyrazolo[3,4- g ]quinoline J. Med. Chem. 1983, 26, 1112-1116
11. Malmberg, A.; Hook, B. B.; Johansson, A. M.; Hacksell, U. Novel (R)-2-Amino-5-fluorotetralins: Dopaminergic Antagonists and Inverse Agonists J. Med. Chem. 1996, 39, 4421-4429 (Pubitemid 26359398)
12. Hackling, A.; Ghosh, R.; Perachon, S.; Mann, A.; Holtje, H. D.; Wermuth, C. G.; Schwartz, J. C.; Sippl, W.; Sokoloff, P.; Stark, H. N -(omega-(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands J. Med. Chem. 2003, 46, 3883-3899
13. Boeckler, F.; Gmeiner, P. Dopamine D3 Receptor Ligands - Recent Advances in the Control of Subtype Selectivity and Intrinsic Activity Biochim. Biophys. Acta, Biomembr. 2007, 1768, 871-887 (Pubitemid 46452549)
14. Löber, S.; Hsbner, H.; Tschammer, N.; Gmeiner, P. Recent Advances in the Search for D3- and D4-Selective Drugs: Probes, Models and Candidates Trends Pharmacol. Sci. [Online early access]. Published Online: January 11, 2011.
15. Huber, D.; H bner, H.; Gmeiner, P. 1,1-Disubstituted Ferrocenes as Molecular Hinges in Mono- and Bivalent Dopamine Receptor Ligands J. Med. Chem. 2009, 52, 6860-6870
16. Dörfler, M.; Tschammer, N.; Hamperl, K.; HLbner, H.; Gmeiner, P. Novel D3 Selective Dopaminergics Incorporating Enyne Units as Nonaromatic Catechol Bioisosteres: Synthesis, Bioactivity, and Mutagenesis Studies J. Med. Chem. 2008, 51, 6829-6838
17. Avenell, K. Y.; Boyfield, I.; Hadley, M. S.; Johnson, C. N.; Nash, D. J.; Riley, G. J.; Stemp, G. Heterocyclic Analogues of 2-Aminotetralins with High Affinity and Selectivity for the Dopamine D3 Receptor Bioorg. Med. Chem. Lett. 1999, 9, 2715-2720 (Pubitemid 29468940)
18. Boyfield, I.; Coldwell, M. C.; Hadley, M. S.; Johnson, C. N.; Riley, G. J.; Scott, E. E.; Stacey, R.; Stemp, G.; Thewlis, K. M. A Novel Series of 2-Aminotetralins with High Affinity and Selectivity for the Dopamine D3 Receptor Bioorg. Med. Chem. Lett. 1997, 7, 1995-1998 (Pubitemid 27338953)
19. Elsner, J.; Boeckler, F.; Heinemann, F. W.; Hobner, H.; Gmeiner, P. Pharmacophore-Guided Drug Discovery Investigations Leading to Bioactive 5-Aminotetrahydropyrazolopyridines. Implications for the Binding Mode of Heterocyclic Dopamine D3 Receptor Agonists J. Med. Chem. 2005, 48, 5771-5779 (Pubitemid 41298349)
20. Chien, E. Y. T.; Liu, W.; Zhao, Q.; Katritch, V.; Won Han, G.; Hanson, M. A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V.; Stevens, R. C. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist Science 2010, 330, 1091-1095
21. Gmeiner, P.; Sommer, J.; Mierau, J.; Höfner, G. Dopamine Autoreceptor Agonists: Computational Studies, Synthesis and Biological Investigations Bioorg. Med. Chem. Lett. 1993, 3, 1477-1483 (Pubitemid 23270172)
22. Bach, N. J.; Kornfeld, E. C.; Jones, N. D.; Chaney, M. O.; Dorman, D. E.; Paschal, J. W.; Clemens, J. A.; Smalstig, E. B. Bicyclic and Tricyclic Ergoline Partial Structures. Rigid 3-(2-Aminoethyl)pyrroles and 3- and 4-(2-Aminoethyl)pyrazoles as Dopamine Agonists J. Med. Chem. 1980, 23, 481-491 (Pubitemid 10153537)
23. Stemp, G.; Johnson, C. N. Preparation of Bicyclic Amine Derivatives and Their Use as Dopamine D3-Receptor (Ant)Agonist Antipsychotic Agents. WO9630333, 1996.
24. Löber, S.; Ortner, B.; Bettinetti, L.; H2bner, H.; Gmeiner, P. Analogs of the Dopamine D4 Receptor Ligand FAUC 113 with Planar- and Central-Chirality Tetrahedron: Asymmetry 2002, 13, 2303-2310 (Pubitemid 35336042)
25. van Vliet, L. A.; Tepper, P. G.; Dijkstra, D.; Damsma, G.; Wikstrom, H.; Pugsley, T. A.; Akunne, H. C.; Heffner, T. G.; Glase, S. A.; Wise, L. D. Affinity for Dopamine D2, D3, and D4 Receptors of 2-Aminotetralins. Relevance of D2 Agonist Binding for Determination of Receptor Subtype Selectivity J. Med. Chem. 1996, 39, 4233-4237 (Pubitemid 26339833)
26. Lane, J. R.; Powney, B.; Wise, A.; Rees, S.; Milligan, G. G Protein Coupling and Ligand Selectivity of the D2L and D3 Dopamine Receptors J. Pharmacol. Exp. Ther. 2008, 325, 319-330 (Pubitemid 351439159)
27. Cordeaux, Y.; Nickolls, S. A.; Flood, L. A.; Graber, S. G.; Strange, P. G. Agonist Regulation of D2 Dopamine Receptor/G Protein Interaction: Evidence for Agonist Selection of G Protein Subtype J. Biol. Chem. 2001, 276, 28667-28675
28. Black, J. W.; Leff, P. Operational Models of Pharmacological Agonism Proc. R. Soc., Ser. B 1983, 220, 141-162 (Pubitemid 14217337)
29. Tschammer, N.; Bollinger, S.; Kenakin, T.; Gmeiner, P. Histidine 6.55 Is a Major Determinant of Ligand Biased Signaling in Dopamine D2L Receptor Mol. Pharmacol. 2011, 79, 575-585
30. Evans, B. A.; Broxton, N.; Merlin, J.; Sato, M.; Hutchinson, D. S.; Christopoulos, A.; Summers, R. J. Quantification of Functional Selectivity at the Human Alpha1A-Adrenoceptor Mol. Pharmacol. 2011, 79, 298-307
31. Kenakin, T. P. 7TM Receptor Allostery: Putting Numbers to Shapeshifting Proteins Trends. Pharmacol. Sci. 2009, 30, 460-469
32. Gay, E. A.; Urban, J. D.; Nichols, D. E.; Oxford, G. S.; Mailman, R. B. Functional Selectivity of D2 receptor Ligands in a Chinese Hamster Ovary hD2L Cell Line: Evidence for Induction of Ligand-Specific Receptor States Mol. Pharmacol. 2004, 66, 97-105 (Pubitemid 38822091)
33. Lane, J. R.; Powney, B.; Wise, A.; Rees, S.; Milligan, G. Protean Agonism at the Dopamine D2 Receptor: (S)-3-(3-Hydroxyphenyl)- N -propylpiperidine Is an Agonist for Activation of Go1 but an Antagonist/Inverse Agonist for Gi1,Gi2, and Gi3 Mol. Pharmacol. 2007, 71, 1349-1359 (Pubitemid 46658688)
34. Chen, J.; Collins, G. T.; Zhang, J.; Yang, C.-Y.; Levant, B.; Woods, J.; Wang, S. Design, Synthesis, and Evaluation of Potent and Selective Ligands for the Dopamine 3 (D3) Receptor with a Novel in Vivo Behavioral Profile J. Med. Chem. 2008, 51, 5905-5908
35. Bartlett, S. E.; Enquist, J.; Hopf, F. W.; Lee, J. H.; Gladher, F.; Kharazia, V.; Waldhoer, M.; Mailliard, W. S.; Armstrong, R.; Bonci, A.; Whistler, J. L. Dopamine Responsiveness Is Regulated by Targeted Sorting of D2 Receptors Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 11521-11526 (Pubitemid 41153852)
36. Thompson, D.; Whistler, J. L. Dopamine D3 Receptors Are Down-Regulated following Heterologous Endocytosis by a Specific Interaction with G Protein-Coupled Receptor-Associated Sorting Protein-1 J. Biol. Chem. 2011, 286, 1598-1608
37. Cho, E.-Y.; Cho, D.-I.; Park, J. H.; Kurose, H.; Caron, M. G.; Kim, K.-M. Roles of Protein Kinase C and Actin-Binding Protein 280 in the Regulation of Intracellular Trafficking of Dopamine D3 Receptor Mol. Endocrinol. 2007, 21, 2242-2254 (Pubitemid 47347385)
38. Ehrlich, K.; Götz, A.; Bollinger, S.; Tschammer, N.; Bettinetti, L.; HÄrterich, S.; HÜbner, H.; Lanig, H.; Gmeiner, P. Dopamine D2, D3, and D4 Selective Phenylpiperazines as Molecular Probes To Explore the Origins of Subtype Specific Receptor Binding J. Med. Chem. 2009, 52, 4923-4935
39. Sartania, N.; Strange, P. G. Role of Conserved Serine Residues in the Interaction of Agonists with D3 Dopamine Receptors J. Neurochem. 1999, 72, 2621-2624 (Pubitemid 29242216)
40. Xhaard, H.; Rantanen, V. V.; Nyronen, T.; Johnson, M. S. Molecular Evolution of Adrenoceptors and Dopamine Receptors: Implications for the Binding of Catecholamines J. Med. Chem. 2006, 49, 1706-1719 (Pubitemid 43376514)
41. Wiens, B. L.; Nelson, C. S.; Neve, K. A. Contribution of Serine Residues to Constitutive and Agonist-Induced Signaling via the D2S Dopamine Receptor: Evidence for Multiple, Agonist-Specific Active Conformations Mol. Pharmacol. 1998, 54, 435-444 (Pubitemid 28368834)
42. Schwartz, T. W.; Frimurer, T. M.; Holst, B.; Rosenkilde, M. M.; Elling, C. E. Molecular Mechanism of 7TM Receptor Activation - A Global Toggle Switch Model Annu. Rev. Pharmacol. Toxicol. 2006, 46, 481-519 (Pubitemid 43271198)
43. Elling, C. E.; Frimurer, T. M.; Gerlach, L.-O.; Jorgensen, R.; Holst, B.; Schwartz, T. W. Metal Ion Site Engineering Indicates a Global Toggle Switch Model for Seven-Transmembrane Receptor Activation J. Biol. Chem. 2006, 281, 17337-17346
44. Bokoch, M. P.; Zou, Y.; Rasmussen, S. G.; Liu, C. W.; Nygaard, R.; Rosenbaum, D. M.; Fung, J. J.; Choi, H. J.; Thian, F. S.; Kobilka, T. S.; Puglisi, J. D.; Weis, W. I.; Pardo, L.; Prosser, R. S.; Mueller, L.; Kobilka, B. K. Ligand-Specific Regulation of the Extracellular Surface of a G-Protein-Coupled Receptor Nature 2010, 463, 108-112
45. Nygaard, R.; Frimurer, T. M.; Holst, B.; Rosenkilde, M. M.; Schwartz, T. W. Ligand Binding and Micro-Switches in 7TM Receptor Structures Trends Pharmacol. Sci. 2009, 30, 249-259
46. Schetz, J. A.; Benjamin, P. S.; Sibley, D. R. Nonconserved Residues in the Second Transmembrane-Spanning Domain of the D4 Dopamine Receptor Are Molecular Determinants of D4-Selective Pharmacology Mol. Pharmacol. 2000, 57, 144-152 (Pubitemid 30033270)
47. Simpson, M. M.; Ballesteros, J. A.; Chiappa, V.; Chen, J.; Suehiro, M.; Hartman, D. S.; Godel, T.; Snyder, L. A.; Sakmar, T. P.; Javitch, J. A. Dopamine D4/D2 Receptor Selectivity Is Determined by a Divergent Aromatic Microdomain Contained within the Second, Third, and Seventh Membrane-Spanning Segments Mol. Pharmacol. 1999, 56, 1116-1126
48. Kortagere, S.; Gmeiner, P.; Weinstein, H.; Schetz, J. A. Certain 1,4-Disubstituted Aromatic Piperidines and Piperazines with Extreme Selectivity for the Dopamine D4 Receptor Interact with a Common Receptor Microdomain Mol. Pharmacol. 2004, 66, 1491-1499 (Pubitemid 39564775)
49. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function J. Comput. Chem. 1998, 19, 1639-1662 (Pubitemid 128590223)
50. Sanner, M. F. Phyton: A Programming Language for Software Integration and Development J. Mol. Graphics Modell. 1999, 17, 57-61 (Pubitemid 30029318)
51. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A Semiempirical Free Energy Force Field with Charge-Based Desolvation J. Comput. Chem. 2007, 28, 1145-1152 (Pubitemid 46506716)
52. Malmberg, A.; Nordvall, G.; Johansson, A. M.; Mohell, N.; Hacksell, U. Molecular Basis for the Binding of 2-Aminotetralins to Human Dopamine D2A and D3 Receptors Mol. Pharmacol. 1994, 46, 299-312
53. Velec, H. F.; Gohlke, H.; Klebe, G. DrugScore(CSD)-Knowledge-Based Scoring Function Derived from Small Molecule Crystal Data with Superior Recognition Rate of Near-Native Ligand Poses and Better Affinity Prediction J. Med. Chem. 2005, 48, 6296-303 (Pubitemid 41428984)
54. Rosenbaum, D. M.; Zhang, C.; Lyons, J. A.; Holl, R.; Aragao, D.; Arlow, D. H.; Rasmussen, S. G. F.; Choi, H.-J.; DeVree, B. T.; Sunahara, R. K.; Chae, P. S.; Gellman, S. H.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Caffrey, M.; Gmeiner, P.; Kobilka, B. K. Structure and Function of an Irreversible Agonist-[beta]2 Adrenoceptor Complex Nature 2011, 469, 236-240
55. Cannon, J. G.; Perez, J. A.; Pease, J. P.; Long, J. P.; Flynn, J. R.; Rusterholz, D. B.; Dryer, S. E. Comparison of Biological Effects of N-Alkylated Congeners of Beta-Phenethylamine Derived from 2-Aminotetralin, 2-Aminoindan, and 6-Aminobenzocycloheptene J. Med. Chem. 1980, 23, 745-749 (Pubitemid 10078470)
56. Tschammer, N.; Dörfler, M.; Hfbner, H.; Gmeiner, P. Engineering a GPCR-Ligand Pair That Simulates the Activation of D2L by Dopamine ACS Chem. Neurosci. 2010, 1, 25-35
57. Rosenkilde, M. M.; Benned-Jensen, T.; Frimurer, T. M.; Schwartz, T. W. The Minor Binding Pocket: A Major Player in 7TM Receptor Activation Trends. Pharmacol. Sci. 2010, 31, 567-574
58. Rasmussen, S. G. F.; Choi, H.-J.; Fung, J. J.; Pardon, E.; Casarosa, P.; Chae, P. S.; DeVree, B. T.; Rosenbaum, D. M.; Thian, F. S.; Kobilka, T. S.; Schnapp, A.; Konetzki, I.; Sunahara, R. K.; Gellman, S. H.; Pautsch, A.; Steyaert, J.; Weis, W. I.; Kobilka, B. K. Structure of a Nanobody-Stabilized Active State of the [beta]2 Adrenoceptor Nature 2011, 469, 175-180
59. Warne, T.; Moukhametzianov, R.; Baker, J. G.; Nehme, R.; Edwards, P. C.; Leslie, A. G. W.; Schertler, G. F. X.; Tate, C. G. The Structural Basis for Agonist and Partial Agonist Action on a [beta]1-Adrenergic Receptor Nature 2011, 469, 241-244
60. Ballesteros, J. A.; Weinstein, H. Integrated Methods for Modeling G-Protein Coupled Receptors Methods Neurosci. 1995, 25, 366-428
61. Vickery, R. G.; von Zastrow, M. Distinct Dynamin-Dependent and -Independent Mechanisms Target Structurally Homologous Dopamine Receptors to Different Endocytic Membranes J. Cell Biol. 1999, 144, 31-43 (Pubitemid 29047009)
62. Hayes, G.; Biden, T. J.; Selbie, L. A.; Shine, J. Structural Subtypes of the Dopamine D2 Receptor Are Functionally Distinct: Expression of the Cloned D2A and D2B Subtypes in a Heterologous Cell Line Mol. Endocrinol. 1992, 6, 920-926
63. Sokoloff, P.; Andrieux, M.; Besancon, R.; Pilon, C.; Martres, M. P.; Giros, B.; Schwartz, J. C. Pharmacology of Human Dopamine D3 Receptor Expressed in a Mammalian Cell Line: Comparison with D2 Receptor Eur. J. Pharmacol. 1992, 225, 331-337
64. Asghari, V.; Sanyal, S.; Buchwaldt, S.; Paterson, A.; Jovanovic, V.; Van Tol, H. H. Modulation of Intracellular Cyclic AMP Levels by Different Human Dopamine D4 Receptor Variants J. Neurochem. 1995, 65, 1157-1165
65. HMbner, H.; Haubmann, C.; Utz, W.; Gmeiner, P. Conjugated Enynes as Nonaromatic Catechol Bioisosteres: Synthesis, Binding Experiments, and Computational Studies of Novel Dopamine Receptor Agonists Recognizing Preferentially the D(3) Subtype J. Med. Chem. 2000, 43, 756-762 (Pubitemid 30127169)
66. Heindl, C.; Hbner, H.; Gmeiner, P. Ex-Chiral Pool Synthesis and Receptor Binding Studies of 4-Substituted Prolinol Derivatives Tetrahedron: Asymmetry 2003, 14, 3141-3152 (Pubitemid 38375885)
67. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein Measurement with the Folin Phenol Reagent J. Biol. Chem. 1951, 193, 265-275
68. Cohen, F. R.; Lazareno, S.; Birdsall, N. J. The Effects of Saponin on the Binding and Functional Properties of the Human Adenosine A1 Receptor Br. J. Pharmacol. 1996, 117, 1521-1529 (Pubitemid 26116780)
69. Jiang, M.; Bajpayee, N. S. Molecular Mechanisms of Go Signaling Neurosignals 2009, 17, 23-41
70. 4 Receptor Partial Agonists: Solid-Phase Synthesis, Binding Assays, and Functional Experiments J. Med. Chem. 2000, 43, 4563-4569 (Pubitemid 32046881)
71. Bettinetti, L.; Schlotter, K.; H.bner, H.; Gmeiner, P. Interactive SAR Studies: Rational Discovery of Super-Potent and Highly Selective Dopamine D3 Receptor Antagonists and Partial Agonists J. Med. Chem. 2002, 45, 4594-4597
72. 50) of an Enzymatic Reaction Biochem. Pharmacol. 1973, 22, 3099-3108
73. Kenakin, T.; Miller, L. J. Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery Pharmacol. Rev. 2010, 62, 265-304
74. Finn, A. K.; Whistler, J. L. Endocytosis of the mu Opioid Receptor Reduces Tolerance and a Cellular Hallmark of Opiate Withdrawal Neuron 2001, 32, 829-839 (Pubitemid 34024844)
75. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A., Jr.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Andres, J. L.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 98, revision A.7; Gaussian, Inc.: Pittsburgh, PA, 1998.
76. Case, D. A.; Darden, T. A.; Cheatham; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Crowley, M.; Walker, R. C.; Zhang, W.; Merz, K. M.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Kolossváry, I.; Wong, K. F.; Paesani, F.; Vanicek, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Mathews, D. H.; Seetin, M. G.; Sagui, C.; Babin, V.; Kollman, P. A. AMBER 10; University of California: San Francisco, CA, 2008.
77. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of Multiple Amber Force Fields and Development of Improved Protein Backbone Parameters Proteins 2006, 65, 712-725 (Pubitemid 44583220)
78. Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A Well-Behaved Electrostatic Potential Based Method Using Charge Restraints for Deriving Atomic Charges: The RESP Model J. Phys. Chem. 1993, 97, 10269-10280